EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Eydenzelt (aflibercept) for multiple ophthalmic conditions including wet age-related macular degeneration, macular edema, and retinal vascular di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Choroidal Neovascularization
• Diabetes Complications
• Macular Edema
• Retinal Vein Occlusion
• Wet Macular Degeneration

Drugs mentioned

• Eydenzelt (aflibercept)

Snippet

Status: Authorised. Therapeutic area: Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion;Choroidal Neovascularization. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 26/06/2026